ライフサイエンスコーパス: antibody-mediated rejection

1 hyperacute rejection but 11 (39%) had acute antibody mediated rejection.

2 R ELISA and microvascular injury observed in antibody mediated rejection.

3 Six-month protocol biopsies showed no antibody-mediated rejection.

4 truggle with the diagnosis and management of antibody-mediated rejection.

5 plantation of non-renal organs, and to treat antibody-mediated rejection.

6 no satisfactory therapies for prevention of antibody-mediated rejection.

7 be used to test biopsies for the presence of antibody-mediated rejection.

8 pressed, indicating separation of T-cell and antibody-mediated rejection.

9 Complement may play a key role in antibody-mediated rejection.

10 ation of macrophages in the allograft during antibody-mediated rejection.

11 ion of the complement cascade is involved in antibody-mediated rejection.

12 pful in excluding chronic, Banff category II antibody-mediated rejection.

13 ing list patients and a better prediction of antibody-mediated rejection.

14 ing the need for a nonhuman primate model of antibody-mediated rejection.

15 mixed chronic T-cell and concurrent chronic antibody-mediated rejection.

16 ic antibodies and 7% of patients experienced antibody-mediated rejection.

17 sitization protocols and to the treatment of antibody-mediated rejection.

18 No patients had antibody-mediated rejection.

19 to the xenograft in the absence of anti-Gal antibody-mediated rejection.

20 phocytes and acute cellular rejection versus antibody-mediated rejection.

21 rily due to the desensitization protocol and antibody-mediated rejection.

22 tion and importantly allowing recognition of antibody-mediated rejection.

23 pret data on the diagnosis and management of antibody-mediated rejection.

24 r follow-up, and at the time of diagnosis of antibody-mediated rejection.

25 All evaluable explanted grafts experienced antibody-mediated rejection.

26 1), there was a nonsignificant difference in antibody-mediated rejection.

27 ensitization and prevention and treatment of antibody-mediated rejection.

28 ntibody manifests characteristic features of antibody-mediated rejection.

29 ntial therapeutic target in the treatment of antibody-mediated rejection.

30 ) is part of the Banff definition of chronic antibody-mediated rejection.

31 tential of TNT009 for preventing or treating antibody-mediated rejection.

32 undergoing desensitization or treatment for antibody-mediated rejection.

33 but grafts are still susceptible to humoral (antibody-mediated) rejection.

34 The incidence of antibody-mediated rejection (25% vs. 12.5%, P=0.008) and

35 nd five DSA- (2%) patients developed chronic antibody-mediated rejection (3%).

36 ]; P=0.001), and in patients with history of antibody-mediated rejection (4.985 [2.77-8.97]; P<0.0001

37 ls (80% vs 55%), especially a higher rate of antibody-mediated rejections (55% vs 11%, P < 0.01) with

38 R (24.3 [11.2, 44.8], P < 0.001, n = 9); and antibody-mediated rejection (6.0 [3.3, 13.7], P = 0.002,

39 reased risk for T cell-mediated rejection or antibody-mediated rejection (68% vs 41%, P = 0.01) and f

40 however, have allowed improved diagnosis of antibody mediated rejection, a relatively recently recog

41 re also associated with an increased rate of antibody-mediated rejection, a more severe graft injury

42 t decade, the diagnostic precision for acute antibody-mediated rejection (aABMR) in kidney transplant

43 Overall, 51 (40.8%) patients had acute antibody-mediated rejection (aABMR), 36 (28.8%) patients

44 on report of the incidence of combined acute antibody-mediated rejection (ABMR) + acute cellular reje

45 st Banff 2013 report recognizes acute/active antibody-mediated rejection (ABMR) and C4d staining with

46 cific antibodies (dnDSA) are associated with antibody-mediated rejection (ABMR) and graft failure aft

47 expression glomerular of capillaries during antibody-mediated rejection (ABMR) are poorly understood

48 Antibody-mediated rejection (ABMR) can occur in patients

49 A) are considered as reliable biomarkers for antibody-mediated rejection (ABMR) diagnosis.

50 e clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting

51 nt glomerulitis (G) is associated with acute antibody-mediated rejection (ABMR) in the presence of do

52 Late antibody-mediated rejection (ABMR) is a leading cause of

53 Antibody-mediated rejection (ABMR) is a leading cause of

54 Antibody-mediated rejection (ABMR) is the leading cause

55 olecules as diagnostic/prognostic markers of antibody-mediated rejection (ABMR) is unknown.

56 ant rates in highly sensitized patients, but antibody-mediated rejection (ABMR) remains a concern.

57 able for the early assessment of response to antibody-mediated rejection (ABMR) therapies in kidney a

58 atients undergoing acute cellular rejection, antibody-mediated rejection (ABMR), and delayed graft fu

59 nd points included rates of transplantation, antibody-mediated rejection (ABMR), and renal function.

60 rejection (TCMR), either pure or mixed with antibody-mediated rejection (ABMR).

61 ng was associated with an increased risk for antibody-mediated rejection (ABMR).

62 lement may contribute to the pathogenesis of antibody-mediated rejection (ABMR).

63 ansplant tolerance, and protecting from late antibody-mediated rejection (ABMR).

64 MR), and 142 (14%) patients with subclinical antibody-mediated rejection (ABMR).

65 osis of T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR).

66 any rejection (T cell-mediated rejection or antibody-mediated rejection [ABMR]) and controls (no rej

67 Defining mechanisms of antibody-mediated rejection, accommodation, and toleranc

68 fter lung transplantation is associated with antibody mediated rejection, acute cellular rejection, a

69 in HLA-sensitized patients and how to treat antibody-mediated rejection after ABO-compatible HLA-inc

70 d to describe endothelial cell resistance to antibody-mediated rejection after ABO-incompatible kidne

71 y contribute to acute cellular rejection and antibody-mediated rejection after liver transplantation.

72 anti-HLA antibodies (DSA) (67% and 82%) and antibody mediated rejection (AMR) (66% and 89%) when com

73 ibody to AT1R on clinical outcomes including antibody mediated rejection (AMR), with or without C4d d

74 s. 34.8%, P=0.01), including higher rates of antibody-mediated rejection (AMR) (32.3% vs. 7.1%, P<0.0

75 s. 34.8%, P=0.01), including higher rates of antibody-mediated rejection (AMR) (32.3% vs. 7.1%, P<0.0

76 34 kidney recipients, 19 with biopsy-proven antibody-mediated rejection (AMR) + and 15 who were AMR-

77 Treatment of patients with antibody-mediated rejection (AMR) after kidney transplan

78 nces of early (< or =30 days posttransplant) antibody-mediated rejection (AMR) and acute cellular rej

79 Eight episodes of mixed antibody-mediated rejection (AMR) and acute cellular rej

80 lpha1-Tubulin (KAT) in pathogenesis of acute antibody-mediated rejection (AMR) and cardiac allograft

81 ibodies (AT1R-abs) have been associated with antibody-mediated rejection (AMR) and decreased graft su

82 ities associated with bortezomib therapy for antibody-mediated rejection (AMR) and desensitization wa

83 e between indolent and harmful dnDSA causing antibody-mediated rejection (AMR) and graft loss.

84 K) cells localize in the microcirculation in antibody-mediated rejection (AMR) and have been postulat

85 o DSA/complement predominates in early-acute antibody-mediated rejection (AMR) and presents with EC s

86 A alloantibodies may cause acute and chronic antibody-mediated rejection (AMR) and significantly comp

87 tion is associated with an increased rate of antibody-mediated rejection (AMR) and subsequent transpl

88 0%) patients with AAD and 1 (3%) control had antibody-mediated rejection (AMR) by endomyocardial biop

89 hallenges facing clinical transplantation is antibody-mediated rejection (AMR) caused by anti-donor H

90 Antibody-mediated rejection (AMR) commonly occurs after

91 Antibody-mediated rejection (AMR) contributes to heart a

92 Histology remains a cornerstone for antibody-mediated rejection (AMR) diagnosis.

93 n (group 1, n=20) or a recent previous acute antibody-mediated rejection (AMR) episode (group 2, n=8)

94 Antibody-mediated rejection (AMR) has been identified am

95 ficacy of plasma cell targeted therapies for antibody-mediated rejection (AMR) has not been defined i

96 led with the formidable risk of irreversible antibody-mediated rejection (AMR) have thus far limited

97 inhibitor, bortezomib, to treat established antibody-mediated rejection (AMR) in 20 patients.

98 ive Syk inhibitor (GS-492429) could suppress antibody-mediated rejection (AMR) in a rat model of AMR

99 nt recipients and is usually associated with antibody-mediated rejection (AMR) in conventional allogr

100 C4d-assisted recognition of antibody-mediated rejection (AMR) in formalin-fixed para

101 (MICA) are associated with the diagnosis of antibody-mediated rejection (AMR) in heart transplant re

102 though several strategies for treating early antibody-mediated rejection (AMR) in kidney transplants

103 fragment C4d and its association with acute antibody-mediated rejection (AMR) in pancreas transplant

104 SPK recipients and has been used to prevent antibody-mediated rejection (AMR) in sensitized kidney t

105 edom from acute cellular rejection (ACR) and antibody-mediated rejection (AMR) in SLK was 93 and 96%

106 tiveness of eculizumab for the prevention of antibody-mediated rejection (AMR) in the setting of rena

107 Antibody-mediated rejection (AMR) is a major cause of ki

108 Antibody-mediated rejection (AMR) is a major cause of ki

109 Antibody-mediated rejection (AMR) is a major risk for re

110 Antibody-mediated rejection (AMR) is a recognized cause

111 Antibody-mediated rejection (AMR) is a severe form of re

112 dentifying immune mechanisms responsible for antibody-mediated rejection (AMR) is an important goal.

113 Antibody-mediated rejection (AMR) is an important proble

114 Antibody-mediated rejection (AMR) is an increasingly rec

115 Antibody-mediated rejection (AMR) is an uncommon, but ch

116 Treatment of acute antibody-mediated rejection (AMR) is based on a combinat

117 In heart transplantation, antibody-mediated rejection (AMR) is diagnosed and grade

118 The common endpoint in the treatment of antibody-mediated rejection (AMR) is functional reversal

119 an leukocyte antigen antibodies (DSA) during antibody-mediated rejection (AMR) is rarely achieved wit

120 Acute antibody-mediated rejection (AMR) is responsible for up

121 allograft failure after an episode of acute antibody-mediated rejection (AMR) may help the outcome o

122 Antibody-mediated rejection (AMR) of most solid organs i

123 The prevalence, risk factors, and outcome of antibody-mediated rejection (AMR) of the kidney after si

124 ral killer (NK) cell-associated genes during antibody-mediated rejection (AMR) of the renal allograft

125 nsplantation) anti-HLA-DSA were diagnosed as antibody-mediated rejection (AMR) or AMR+T-cell-mediated

126 Antibody-mediated rejection (AMR) represents one of the

127 Antibody-mediated rejection (AMR) resulting in transplan

128 A proposed chronic antibody-mediated rejection (AMR) score has recently pre

129 The risk of antibody-mediated rejection (AMR) was higher in the dnDS

130 Among transplant recipients, antibody-mediated rejection (AMR) was more frequent in g

131 transplant recipients with an early or late antibody-mediated rejection (AMR), acute cellular reject

132 nt, de novo donor-specific antibodies (DSA), antibody-mediated rejection (AMR), acute cellular reject

133 antidonor antibodies results in accelerated antibody-mediated rejection (AMR), complement activation

134 In the treatment of refractory antibody-mediated rejection (AMR), splenectomy has been

135 apy.Fifteen (29%) of 52 patients experienced antibody-mediated rejection (AMR), whereas 37 (71%) pati

136 ntibodies (DSA) mediate hyperacute and acute antibody-mediated rejection (AMR), which can lead to ear

137 r before transplantation or as treatment for antibody-mediated rejection (AMR).

138 pathology, particularly in acute and chronic antibody-mediated rejection (AMR).

139 is associated with increased mortality from antibody-mediated rejection (AMR).

140 d transplant that has acquired resistance to antibody-mediated rejection (AMR).

141 rkers are needed that identify patients with antibody-mediated rejection (AMR).

142 tuximab and to identify patients at risk for antibody-mediated rejection (AMR).

143 ching strategies to reduce the occurrence of antibody-mediated rejection (AMR).

144 f transplantation leads to acute and chronic antibody-mediated rejection (AMR).

145 d arrays may not inevitably indicate ongoing antibody-mediated rejection (AMR).

146 aft function as well as in acute and chronic antibody-mediated rejection (AMR).

147 (CNI) toxicity while effectively preventing antibody-mediated rejection (AMR).

148 positive group (P < 0.001), primarily due to antibody-mediated rejection (AMR, 13% vs. 1.8%, P < 0.00

149 Three antibody-mediated rejections (AMRs) occurred without det

150 ased donors, new immunosuppression regimens, antibody mediated rejection and the regulatory environme

151 nguished acute cellular rejection from acute antibody-mediated rejection and borderline rejection (AU

152 rphologic evidence of an association between antibody-mediated rejection and de novo MG, because both

153 transplanted organ are at increased risk of antibody-mediated rejection and development of transplan

154 Of the 17 biopsy-proven episodes, 12 were antibody-mediated rejection and five were acute cellular

155 and potentially progressive diseases such as antibody-mediated rejection and glomerulonephritis.

156 ose that fix complement, are associated with antibody-mediated rejection and graft failure.

157 is a major risk factor for acute and chronic antibody-mediated rejection and graft loss after all sol

158 lants can be accomplished with a low risk of antibody-mediated rejection and graft loss using plasmap

159 avoided due to their strong association with antibody-mediated rejection and graft loss.

160 pecific antibodies (DSA) are associated with antibody-mediated rejection and graft loss.

161 fic antibodies (dnDSA) and can contribute to antibody-mediated rejection and graft loss.

162 ransplantation without incurring the risk of antibody-mediated rejection and immediate graft loss.

163 s from transplantation patients with chronic antibody-mediated rejection and in panel-reactive antibo

164 odel with which to investigate mechanisms of antibody-mediated rejection and novel therapeutic approa

165 dies (donor-specific antibody) contribute to antibody-mediated rejection and poor long-term graft sur

166 ind any association between the frequency of antibody-mediated rejection and pretransplant proportion

167 riteria for the diagnosis of liver allograft antibody-mediated rejection and provide a comprehensive

168 specially those awaiting DD, with acceptable antibody-mediated rejection and survival rates at 24 mon

169 positive crossmatch carry increased risk of antibody-mediated rejection and thus graft loss.

170 ibiotics is limited by co-existent T-cell or antibody-mediated rejection and underlying chronic allog

171 acute T cell-mediated rejection and 26 acute antibody-mediated rejection) and 32 urine samples from 3

172 L-6 in mediation of cell-mediated rejection, antibody-mediated rejection, and chronic allograft vascu

173 st-transplant donor-specific HLA antibodies, antibody-mediated rejection, and early transplant glomer

174 ary macrophage infiltration is a hallmark of antibody-mediated rejection, and macrophages are importa

175 on of de novo donor-specific antibody (DSA), antibody-mediated-rejection, and unfavorable transplanta

176 nff 3-Borderline, Banff 4-I/II/III), Banff-2 antibody-mediated rejection, Banff-5 interstitial fibros

177 Of the patients with antibody-mediated rejection (biopsy proven or empiric),

178 is a diagnostic criterion for chronic active antibody-mediated rejection (CAABMR), with C4d, donor-sp

179 s (dnDSA) is associated with late or chronic antibody-mediated rejection (CAMR) and poor graft outcom

180 The incidence of chronic antibody-mediated rejection (CAMR) based on surveillance

181 evels were higher in patients diagnosed with antibody mediated rejection compared to those with no re

182 s of concurrent acute cellular rejection and antibody-mediated rejection confirmed by demonstration o

183 ed rejection and changes suggestive of acute antibody-mediated rejection, diagnosed after the first y

184 ced acute cellular rejection, and especially antibody-mediated rejection, displayed persistent elevat

185 significantly higher incidence of subsequent antibody-mediated rejection episodes (P < 0.001), but re

186 west DSA thresholds associated with inferior antibody-mediated rejection-free graft survival (75% vs.

187 The transcripts distinguishing antibody-mediated rejection from other conditions were m

188 The role of the complement system in antibody-mediated rejection has been investigated in rel

189 elicit well characterized manifestations of antibody-mediated rejection has not been tested.

190 However, improvement in the diagnosis of antibody-mediated rejection has not yet translated into

191 trophy of skin and other tissues, as well as antibody mediated rejection, have not been reported in a

192 rations have been used to successfully treat antibody mediated rejection in kidney transplant recipie

193 orcine carbohydrate genes necessary to avoid antibody-mediated rejection in a pig-to-human model also

194 C4d is a useful marker of antibody-mediated rejection in cardiac and renal transpl

195 Humoral or antibody-mediated rejection in cardiac transplant recipi

196 ce of serum alloantibody, C4d deposition and antibody-mediated rejection in human patients.

197 ely reflects the glomerular changes of acute antibody-mediated rejection in humans and of a special s

198 the recently described C4d-negative chronic antibody-mediated rejection in humans.

199 lled all diagnostic criteria for acute renal antibody-mediated rejection in humans.

200 ion, might constitute a diagnostic triad for antibody-mediated rejection in lung transplant patients.

201 and challenges surrounding the diagnosis of antibody-mediated rejection in lung transplantation.

202 be a novel molecular target for controlling antibody-mediated rejection in organ transplantation.

203 dies we have shown an increased incidence of antibody-mediated rejection in patients with pretranspla

204 ve been involved in the majority of cases of antibody-mediated rejection in solid organ transplant re

205 ecipients of kidney transplants experiencing antibody-mediated rejection in the absence of donor-spec

206 We also evaluated for increased evidence of antibody-mediated rejection in the de novo group, as som

207 To confirm the role of antibody-mediated rejection in the sensitized recipients

208 eatment with donor-derived dexDCs induces an antibody-mediated rejection in this islet transplantatio

209 We confirmed our results in a mouse model of antibody-mediated rejection, in which B6.RAG1(-/-) recip

210 These transplants exhibited features of antibody-mediated rejection including capillaritis with

211 The hazard ratio for antibody-mediated rejection increased linearly with high

212 Antibody-mediated rejection is a leading cause for renal

213 Antibody-mediated rejection is a major complication in r

214 Despite advances in immunosuppression, antibody-mediated rejection is a serious threat to allog

215 Chronic antibody-mediated rejection is an important cause of lat

216 Antibody-mediated rejection is caused in part by increas

217 Antibody-mediated rejection is the major cause of kidney

218 Antibody-mediated rejection is therefore dependent on Tf

219 ransplantation, especially in the context of antibody-mediated rejection, its histological interpreta

220 ent, with recurrence, subsequently developed antibody-mediated rejection leading to graft failure.

221 hyperacute rejection and 1 episode of early antibody-mediated rejection (<90 days) in the imported V

222 C4d-negative antibody-mediated rejection manifesting as capillaritis

223 C4d-negative antibody-mediated rejection manifesting as capillaritis

224 Antibody-mediated rejection manifests with glomerular an

225 Antibody-mediated rejection occurred in 10 patients (7 p

226 Antibody-mediated rejection occurred in 28% of ABO-incom

227 lf life of the drug, and (5) induce a potent antibody mediated rejection of target cells.

228 Complement activation plays a major role in antibody-mediated rejection of allografts (AMR); C4d is

229 ase-like molecule, as a biomarker of chronic antibody-mediated rejection of human kidneys when measur

230 recipient T cell sensitization may result in antibody-mediated rejection of renal allografts and intr

231 dies is consistent with previous findings in antibody-mediated rejection of renal and cardiac transpl

232 Twenty-four subjects (61%) developed acute antibody-mediated rejection of the allograft and one pat

233 However, antibody-mediated rejection of the kidney in CLK has bee

234 Antibody-mediated rejection often is accompanied by hemo

235 tential, fms-I-treated rats developed severe antibody-mediated rejection on day 8 after transplantati

236 es with scores>0.5, 39 had been diagnosed as antibody-mediated rejection on the basis of histology an

237 sies performed because of graft dysfunction, antibody-mediated rejection or acute tubular necrosis, a

238 t translate into increased acute cellular or antibody-mediated rejection or reduced survival.

239 Arteritis was associated with subsequent antibody-mediated rejection (OR=4.9, 95% CI=1.1-20.8, P=

240 jection (P = 0.0001) and not associated with antibody-mediated rejection (P = 0.16).

241 R or DQ alone, P=0.001, and were at risk for antibody-mediated rejection, P=0.001.

242 Research challenged the conventional view of antibody-mediated rejection pathophysiology and discusse

243 ore than or equal to 1 year grafts is mostly antibody-mediated rejection related, correlates with chr

244 ossmatch result, nearly doubles the risk for antibody-mediated rejection (relative risk [RR], 1.98; 9

245 Diagnosis of antibody-mediated rejection required presence of diffuse

246 ay data to develop classifiers that assigned antibody-mediated rejection scores to each biopsy.

247 Antibody-mediated rejection seems to constitute the majo

248 ecently been introduced for the treatment of antibody-mediated rejection, target the ubiquitously-exp

249 The pathologic manifestations of acute antibody-mediated rejection that has progressed to funct

250 Although widely used as a marker for antibody-mediated rejection, the significance of C4d in

251 the ptc score is a diagnostic criterion for antibody-mediated rejection, the utility of diffuse ptc

252 ll-mediated rejection was more frequent than antibody-mediated rejection throughout follow-up.

253 ll-mediated rejection was more frequent than antibody-mediated rejection throughout follow-up.

254 y assigned diagnoses, including C4d-negative antibody-mediated rejection, to 403 indication biopsies

255 eloped DQ DSAbs were at significant risk for antibody-mediated rejection, transplant glomerulopathy,

256 Antibody-mediated rejection triggered by alloantibody bi

257 transplantation carries an increased risk of antibody-mediated rejection, ultimately these transplant

258 Cellular and antibody-mediated rejection was absent or minimal in ear

259 Antibody-mediated rejection was assessed by morphology/i

260 Antibody-mediated rejection was diagnosed in 6 patients

261 Antibody-mediated rejection was diagnosed using Antibody

262 Antibody-mediated rejection was evident in 15/17 A-Tg gr

263 No evidence for antibody-mediated rejection was found.

264 Antibody-mediated rejection was investigated using hyper

265 Antibody-mediated rejection was not observed in A-Tg gra

266 Antibody-mediated rejection was not observed on biopsy.

267 Antibody-mediated rejection was observed in 3 (0.03%) pa

268 C4d staining without antibody-mediated rejection was present in 13 (52%) 25 e

269 iated with unanimity among pathologists that antibody-mediated rejection was present.

270 Imaging studies indicated that antibody-mediated rejection was very rapid (<3 hours) in

271 ts of T cell depletion in the development of antibody-mediated rejection were examined using human CD

272 Banff 97 criteria and features suggestive of antibody-mediated rejection were noted.

273 Cellular- and antibody-mediated rejections were statistically higher i

274 Overlapping histologic findings can occur in antibody-mediated rejection, which is characterized by p

275 of immune tolerance, with a low incidence of antibody-mediated rejection, which is in sharp contrast

276 Renal biopsy revealed acute and chronic antibody-mediated rejection with glomerular thrombi and

277 allografts resembled human acute and chronic antibody-mediated rejection with glomerulitis, microthro

278 arteritis (v) lesion (TCMRV; n = 78), total antibody-mediated rejection with v lesion (AMRV), which

279 distinguishes T cell-mediated rejection from antibody-mediated rejection, with a cross-validated esti

280 Three patients experienced antibody-mediated rejection within 2 weeks of transplant